Stroke Drug Development Targeting Nogo-A

Ischemic stroke significantly increases the expression of Nogo-A, which in turn causes a number of pathological changes, including reduced nerve fiber growth, inhibition of cerebral vascular repair, and reduced neuronal survival. That suggests that elevated Nogo-A induced by stroke exacerbates the pathological process of stroke. It has been verified that the use of Nogo-A antibodies to neutralize Nogo-A after stroke is an effective way to treat stroke. With this in mind, Ace Therapeutics offers comprehensive services to treat stroke by inhibiting the expression of Nogo-A.

Development of Small Molecule Inhibitors Targeting Nogo-A for Stroke

In view of the deleterious effects of stroke caused by elevated Nogo-A expression, Ace Therapeutics offers comprehensive services for the development of small molecule inhibitors targeting Nogo-A.

• Based on our ultra-large small molecule library, including compound libraries, natural product libraries, and fragment libraries, we conduct a large-scale screening of small molecule inhibitors targeting Nogo-A through different drug screening platforms to increase the success rate of candidate inhibitor discovery.
• We screen the compounds obtained from the screening in an in vitro stroke model to obtain candidate inhibitors with significant therapeutic effects.
• For those candidates with significant effects, we further evaluate them in in vivo stroke models and explore their detailed mechanisms of action.

Development of Anti-Nogo-A Antibody for Stroke

Antibodies against Nogo-A have been shown to be significantly effective in the treatment of stroke, while antibodies against Nogo-A have been shown to be safe in phase I clinical trials in acute spinal cord injury. Thus, antibodies against Nogo-A are an effective treatment for stroke. In view of this, Ace Therapeutics offers comprehensive services to develop therapeutic antibodies targeting Nogo-A for the treatment of stroke.

• We provide quality services to generate human-mouse chimeric and humanized antibodies targeting Nogo-A.
• Due to the adverse effects of heterologous antibodies, we have established phage antibody library technology for stroke-related drug targets, which allows us to rapidly obtain more fully humanized antibodies and can minimize the side effects of heterologous effects on humans.
• We can produce fully humanized antibodies by phage display technology, transgenic mouse technology, ribosome display technology, RNA-peptide technology, and other assays.

At the same time, in view of the adverse effects of heterologous antibodies, we have continued to develop and optimize the technology of the humanization of antibodies and the technology of producing fully humanized antibodies. We are committed to improving the affinity of antibodies, reducing the heterogenicity of antibodies, and making therapeutic antibodies play a greater role. If you would like to learn more about our services, please feel free to contact us.

1. Rust, R., et al., Nogo-a targeted therapy promotes vascular repair and functional recovery following stroke. Proc Natl Acad Sci U S A, 2019. 116(28): p. 14270-14279.